|CRDAMC Homepage | CRDAMC Library Phone #: (254) 288-8366 | CRDAMC Library Fax #: (254) 288-8368|
by Debra Wood, RN
Tardive dyskinesia (TD) is a neurological syndrome. It results from using antipsychotic drugs. This class of drugs is used to treat psychiatric conditions, like schizophrenia. TD consists of a group of symptoms including:
It is unclear exactly why Tardive dyskinesia develops. Long-term use of antipsychotics can cause changes in the brain chemistry that lead to the symptoms. Nerve cells may also become overly sensitive to certain substances. Not everyone who takes these drugs develops TD.
Risk Factors TOP
Tardive dyskinesia (TD) is more common in women and in people over the age of 54. Other factors that may increase your risk of TD include:
Tardive dyskinesia (TD) causes repetitive movements. Movements usually occur in the face, mouth, limbs, or trunk. The movements are involuntary and serve no purpose. They may occur occasionally or all of the time. They may or may not be noticeable. Symptoms may begin while on the drug or within weeks of stopping it.
Symptoms may include:
They can worsen with:
Symptoms may decrease with:
The doctor will ask about your symptoms and medical history. A physical exam will be done. Other disorders can cause symptoms similar to those of Tardive dyskinesia (TD). The doctor will rule out other disorders before making a diagnosis. There is no specific test for TD.
Tests to rule out other disorders may include:
To treat Tardive dyskinesia, your doctor may:
Symptoms may decrease over time even if you continue to take the antipsychotic drug. Younger people tend to do better.
Some medications may help decrease symptoms, such as:
Deep Brain Stimulation (DBS) is being evaluated for the treatment of Tardive dyskinesia.
To help reduce your chances of TD from an antipsychotic drug:
National Alliance on Mental Illness
National Institute of Neurological Disorders and Stroke
Canadian Mental Health Association
Mental Health Canada
Bai YM, Yu SC, Linn CC. Risperidone for severe tardive dyskinesia: A 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(11):1342-1348.
Damier P. Drug-induced dyskinesias. Curr Opin Neurol. 2009;22(4):394-399.
Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(6):985-996.
McGrath JJ, Soares KV. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2006;(1):CD000459.
Meco G, Fabrizio E, Epifanio A. Levetiracetam in tardive dyskinesia. Clin Neuropharmacol. 2006;29(5):265-268.
Pham DQ, Plakogiannis R. Vitamin E supplementation in Alzheimer’s disease, Parkinson’s disease, tardive dyskinesia, and cataract: Part 2. Ann Pharmacother. 2005;39(12):2065-2072.
Sachdev PS. The current status of tardive dyskinesia. Australian and New Zealand Journal of Psychiatry. 2000;34(3):355-369.
Soares KV, McGrath JJ. The treatment of tardive dyskinesia: A systematic review and meta-analysis. Izophr Res. 1999;39(1):1-16.
Tardive dyskinesia. EBSCO DynaMed Plus website. Available at: http://www.dynamed.com/topics/dmp~AN~T113751/Tardive-dyskinesia. Updated June 8, 2015. Accessed May 14, 2016.
Thema B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesias: passing the baton to pharmacogenetics. Pharmacogenomics. 2008;9(9):1285-1306.
Last reviewed May 2016 by Rimas Lukas, MD
Last Updated: 6/2/2014